Trials Sponsors Conditions Drugs Pricing

Conditions

Breast Cancer Breast Neoplasms Cancer, Breast

Keywords

Circulating tumor cellsCTCCirculating tumor DNActDNAGenomicsTranscriptomics

Outcome Measures

Primary Outcomes (1)

Pathologic complete response (pCR)
Evaluating the degree of absence of residual cancer cells
Up to 60 months

Secondary Outcomes (3)

Time to distant breast cancer recurrence (months)
Up to 60 months
Time to any recurrence (months)
Up to 60 months
Time to death

Interventions

Genomic Markers (CTC/ctDNA)Diagnostic test

This is a non-interventional study.

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

This study will enroll women and men with a pathologically-confirmed diagnosis of invasive breast cancer that is stage I-III according to the AJCC v7 criteria.

You may qualify if:

Subjects must give appropriate written informed consent prior to participation in the study.

Sponsors & Collaborators

Sunnybrook Health Sciences Centre
Otherlead

Study Sites (1)

Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples

MeSH Terms

Conditions

Breast NeoplasmsNeoplastic Cells, Circulating

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesNeoplasm MetastasisNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Katarzyna J Jerzak, MD, MSc, FRCPC
Sunnybrook Health Sciences Centre
PRINCIPAL INVESTIGATOR

Enrollment

100 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Target Duration: 5 Years
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Medical Oncologist & Associate Scientist

Study Record Dates

First Submitted

October 12, 2018

First Posted

October 17, 2018

Study Start

October 1, 2019

Actual (reported)

Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations